Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCLC

Cui Xia Zheng, Shuang Xia Zhao, Ping Wang, Hui Min Yu, Cao Fu Wang, Bing Han, Bin Su, Yi Xiang, Xue Song Li, Sheng Xian Li, Qin Yun Ma, Rong Xin Zhang, Huan Ying Wan, Huai Dong Song

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Mimecan mRNA was present in a limited number of mouse and human tissues, however, abundant mimecan mRNA was observed in the lung tissue. Therefore, we hypothesize that mimecan could serve as a biomarker for differentiating various histological types of lung cancers. In humans, the mimecan mRNA was found most abundant in ovary and less abundant in lung by using Northern blot analysis. Moreover, the mimecan was expressed strongly in the epithelial cells of the bronchial wall and weaker in the epithelial cells of the alveolar sacs by in situ hybridization and immunohistochemical analysis. Furthermore, the mimecan immunoreactivity was found in 103 (97.2%) of 106 non-small cell lung cancers (NSCLCs). Nevertheless, a large majority of small cell lung cancers (SCLCs) (50/56, 89.3%) showed negative immunoreactivity to mimecan polyclonal antibody. A significant difference of mimecan immunoreactivity was found between NSCLC and SCLC (P<0.00001). This is the first study showing that mimecan could serve as an excellent pathological biomarker to distinguish NSCLCs from SCLCs.

Original languageEnglish (US)
Pages (from-to)1057-1061
Number of pages5
JournalOncology reports
Issue number5
StatePublished - 2009
Externally publishedYes


  • Differential diagnosis
  • Mimecan
  • Molecular biomarker
  • Non-small cell lung cancers
  • Small cell lung cancers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCLC'. Together they form a unique fingerprint.

Cite this